News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 361–396
- Matches
- 887
- Sources here
- 19
- Companies here
- 14
Search results
Stored financial headlines
Active search
887 matching headlines
Ticker or company: IAGMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
Cardio Diagnostics Holdings, Inc. announced it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will cover the company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available …
CDIO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -44.6% · Next-week setup negative 42.7%
Cardio Diagnostics (NASDAQ: CDIO) plans vote on sizable new stock issuance
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is seeking stockholder approval for a significant new stock issuance proposal at its virtual annual meeting on September 18, 2026. The company plans to vote on issuing up to 5.0 million shares or equivalents, valued at up to …
CDIO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -44.6% · Next-week setup negative 42.7%
Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2026, Qiagen (QGEN) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $527.94 …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
Niagen Bioscience (NAGE) is gaining attention after a new study linked its Niagen nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. Despite recent stock price declines, the company's valuation is seen as undervalued at $2.96 compared to a fair value of $12.60, driven …
NAGE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -69.7% · Next-week setup negative 43.5%
Carriage Services (NYSE:CSV) Releases FY 2026 Earnings Guidance
Carriage Services (NYSE:CSV) has released its FY 2026 earnings guidance, projecting EPS of $3.35–$3.55 and revenue of $435 million–$445 million, aligning closely with analyst expectations. The company recently exceeded Q1 earnings estimates with $0.86 EPS but missed revenue forecasts. Carriage Services also declared a …
CSV
main company
Sharemaestro market context
Price below Trend Line
52 weeks -19.5%
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) exceeded Q2 earnings and revenue estimates, reporting $0.62 per share against a $0.60 consensus and revenues of $535.04 million, surpassing the $527.91 million estimate. Despite the beat, the company's shares have underperformed the S&P 500 year-to-date, and its Zacks Rank of #4 …
QGEN
main company
Sharemaestro market context
Price above Trend Line
52 weeks -14.1%
Arrowstreet Capital Limited Partnership Purchases New Shares in Quest Diagnostics Incorporated $DGX
Arrowstreet Capital Limited Partnership initiated a new position in Quest Diagnostics (NYSE:DGX) by acquiring 11,468 shares valued at approximately $2.25 million. This move comes as institutional investors now own 88.06% of the company, and several analysts have raised price targets following Quest Diagnostics' strong …
DGX
main company
Sharemaestro market context
Trend signal active
52 weeks +31.8% · Next-week setup positive 58.1%
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Niagen Bioscience (NAGE.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding Niagen Bioscience's stock performance.
NAGE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -69.7% · Next-week setup negative 43.5%
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company also highlighted strategic advancements, including the launch of its Niagen Plus telehealth platform and the introduction of NB4168, a pharmaceutical …
NAGE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -69.7% · Next-week setup negative 43.5%
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience Inc (NAGE) reported robust Q2 2026 results, driven by significant e-commerce growth, particularly on its TrueNiagen website and Amazon, and impressive expansion in the China cross-border market. The company is strategically diversifying into new high-growth verticals like skincare and IV/injection therapies, backed …
NAGE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -69.7% · Next-week setup negative 43.5%
Is Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Quest Diagnostics (DGX) has drawn fresh attention after raising its full year 2026 revenue and earnings guidance, alongside reporting second quarter results that showed …
DGX
main company
Sharemaestro market context
Trend signal active
52 weeks +31.8% · Next-week setup positive 58.1%
Earnings Preview: IMDX to Report Financial Results Post-market on August 10
This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.
IMDX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +66.8%
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Buy" by Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus "Buy" rating from five brokerages, with an average 12-month price target of $10.33. Despite the positive analyst sentiment, the company's shares recently traded down to $3.06, near its 52-week low. Institutional investors hold a significant 15.41% …
NAGE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -69.7% · Next-week setup negative 43.5%
Quest Diagnostics (DGX) Stock May Be 32% Undervalued As Guidance Rises
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Quest Diagnostics stock has climbed strongly over the past few years, yet current valuation checks suggest the shares may still trade below an estimate …
DGX
main company
Sharemaestro market context
Trend signal active
52 weeks +31.8% · Next-week setup positive 58.1%
Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria
Lucid Diagnostics (Nasdaq: LUCD) announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy for its EsoGuard Esophageal DNA Test, effective July 2026. This policy deems EsoGuard medically necessary for non-invasive screening of esophageal precancer and cancer …
LUCD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -12.0%
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics Inc. announced that Concert, a healthcare technology company, has issued a positive coverage policy for its EsoGuard® Esophageal DNA Test. This policy, effective July 2026, recognizes EsoGuard as medically necessary for non-invasive screening of esophageal precancer and cancer in patients meeting ACG …
LUCD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -12.0%
Liberty Metals Appoints Former IAMGOLD President & CEO Steve Letwin as Non-Executive Director
Liberty Metals Limited (ASX:LIB) has appointed Steve Letwin, former President and CEO of IAMGOLD Corporation, as a Non-Executive Director, effective August 5, 2026. Mr. Letwin brings over four decades of experience in the global resources and energy sectors, including corporate finance, operational management, and …
IAG
main company
Sharemaestro market context
Price above Trend Line
52 weeks +108.7%
Janus Henderson Group PLC Makes New Investment in Qiagen N.V. $QGEN
Janus Henderson Group PLC has made a new investment in Qiagen N.V., purchasing 366,661 shares valued at approximately $14.6 million, giving it a 0.18% stake. Other institutional investors have also adjusted their holdings, with institutional ownership of Qiagen reaching 70%. Analyst sentiment for Qiagen …
QGEN
main company
Sharemaestro market context
Price above Trend Line
52 weeks -14.1%